Connect with us

Business

RFK Jr.’s vaccine panel postpones vote on whether to delay babies’ first hepatitis B shot

Published

on

RFK Jr.’s vaccine panel postpones vote on whether to delay babies’ first hepatitis B shot


Health and Human Services Secretary Robert F. Kennedy Jr.’s hand-picked vaccine panel on Friday postponed a vote on whether to delay the first dose of the hepatitis B shot from birth to at least one month for most babies born in the U.S.

The decision means that the committee’s current recommendation – that all infants receive a hepatitis B vaccine within 24 hours of birth – will stay in place until the group meets again at a later date. It’s unclear when the panel, called the Advisory Committee on Immunization Practices, or ACIP, will convene again to discuss the hepatitis B shot.

ACIP was considering whether to delay the first dose of the vaccine until at least one month of age for babies of women who test negative for hepatitis B. That would change a safe and highly effective birth dose recommendation that was introduced in 1991 and is credited with virtually eliminating the disease in young kids. 

Some advisors defended the birth dose recommendation during the meeting, saying that delaying it could introduce potential risks to babies, including more infections. But others, particularly those who are known vaccine critics, cast doubt on the safety of administering the vaccine to babies so soon.

Dr. Robert Malone, who gained notoriety for promoting Covid misinformation, brought the motion to postpone the vote.

“I believe that there’s enough ambiguity here and enough remaining discussion about safety, effectiveness and timing that I believe that a vote today would be premature,” Malone said.

All 12 members supported the motion. Dr. Cody Meissner, a professor of pediatrics at the Dartmouth Geisel School of Medicine, said, “I don’t think there’s any question whatsoever that the benefit [of the birth dose] far outweighs any adverse side effects.”

The postponed vote only affects the timing of the first dose of the hepatitis B vaccine series. The second would still be given one-to-two months after birth, with a third dose between six and 18 months of age. 

Also on Friday, the group voted to recommend hepatitis B testing for all pregnant women. The Centers for Disease Control and Prevention, whose most recent director was ousted by the Trump administration, has to sign off on the committee’s new and future recommendations.

The panel’s closely watched two-day meeting in Atlanta comes after Kennedy gutted the committee and appointed 12 new members, including some well-known vaccine critics. ACIP sets recommendations on who should receive certain shots and which vaccines insurers must cover at no cost, raising concerns among health experts that Kennedy’s reshaped panel could curb access to safe and effective immunizations.

The hepatitis B shot has been a life-saving public health intervention against the disease, which can lead to severe health problems, including liver cancer and failure, and death. Acute hepatitis B infections reported among children and teens dropped by 99% between 1990 and 2019, some studies said. The American Academy of Pediatrics says that the so-called birth dose is critical to reduce chronic hepatitis B later in life. 

On Thursday, advisors and other scientific experts clashed over the safety of the birth dose.

“I believe that this vaccine is absolutely critical for babies that are treated,” said member Retsef Levi, who has been vocal about his opposition to RNA vaccines. “But this notion that we sit here with very lousy evidence and argue there is no problem whatsoever [with administering the shot at birth] is not building trust, and it’s not scientific and it’s not what the public here should expect from us.”

But Meissner said that changing the recommendation will “increase the risk of harm based on no evidence of benefit.” He said there will be fewer children who get the full hepatitis B vaccine series, adding that administering the shot at birth in the hospital ensures that babies at least receive their first dose.

“As people have asked, why would we pick one month? Why two? There’s no evidence that it’s safer at a later time,” Meissner said. “It’s an extremely safe vaccine, a very pure vaccine. So I think we will be creating new doubts in the minds of the public that are not justified.”

Ahead of the vote, the American Medical Association strongly urged the panel to keep the birth dose recommendation in place. Other experts outside of the panel also expressed concern about changing the guidance.

“I have not seen any data that says that there is benefit to the infant of waiting a month but there are a number of potential harms to the incident of waiting a month,” said Dr. Adam Langer, a CDC epidemiologist who gave a presentation on the hepatitis B birth dose, ahead of the vote.

During his presentation, Langer said, “the sooner that the hepatitis B vaccine is provided after birth, the greater its effectiveness in preventing perinatal transmission.” That refers to when an infant becomes infected from its mother during birth.

Merck, which manufactures one of the vaccines used starting at birth, pushed back on the proposed recommendation ahead of the panel’s official vote on Thursday. 

“The reconsideration of the newborn Hepatitis B vaccination on the established schedule poses a grave risk to the health of children and to the public, which could lead to a resurgence of preventable infectious diseases,” Dr. Richard Haupt, Merck’s head of global medical and scientific affairs for vaccines and infectious diseases, said during the meeting. 

GSK manufactures another hepatitis B shot starting at birth.



Source link

Business

Pets at Home hoping for boost under new boss despite consumer pressure

Published

on

Pets at Home hoping for boost under new boss despite consumer pressure


Pets at Home investors will be hoping the retailer’s new boss can lay out a strategy to return it to profit growth despite a challenging consumer backdrop.

Shares in the company currently sit close to its lowest level for almost seven years following a recent downturn in the group’s retail arm.

The dip in the group’s performance contributed to the departure of previous chief executive Lyssa McGowan late last year.

In March, former Waitrose boss James Bailey took the reins in a bid to drive a turnaround in performance.

Shareholders will be hoping the new boss can show early signs of improvement and a long-term strategy to drive growth in Pets at Home’s update on Wednesday May 27.

EK6R79 Pets at home interior store space

The pet products retailer and vet chain is expected to report an underlying pre-tax profit of around £93 million for the year to March, according to analysts.

It would represent a roughly 30% fall from last year, after the company came under pressure from weak demand for discretionary products.

Analysts have said investors will be looking at early trading in the current financial year to see how consumer spending is holding up.

AJ Bell’s investment director Russ Mould said: “Pets at Home could badly do with some renewed pep.

“Under executive chair Ian Burke, who has returned to a non-executive role after leading the business on an interim basis, Pets at Home laid out a plan to fix a retail business which has been badly affected by a reduction in discretionary spend on toys and treats for Britons’ furry and feathered friends.

“The country may have a reputation for loving their animal companions but in an environment where households are having to watch their pennies, these nice-to-have items were off the list.”

The group has also seen sales of pet food and similar products face fierce pricing competition from non-specialist retailers, such as supermarkets.

It has since cut prices among around 1,000 products in order to help drive activity, with cash-strapped shoppers looking for value.

Data from the Office for National Statistics (ONS) showed that UK retail sales volumes dropped to an 11-month low in April, with a 1.3% fall for the month.

Pets at Home is predicted to report revenues of £1.47 billion for the past year, just marginally lower than £1.482 billion reported last year.



Source link

Continue Reading

Business

India’s fuel demand growth may slow sharply in H2 2026 amid price hikes, austerity push: Report

Published

on

India’s fuel demand growth may slow sharply in H2 2026 amid price hikes, austerity push: Report


India’s transportation fuel demand growth is expected to slow sharply in the second half of 2026 as higher fuel prices, government-led conservation measures and a weakening rupee weigh on mobility and consumption trends, according to a report.The report by Kpler’s lead analyst (modelling), Elif Binici, revised down India’s 2026 refined products demand growth forecast by around 77,000 barrels per day (kbd), or 39 per cent, to nearly 78 kbd from an earlier estimate of 128 kbd.As per news agency PTI, the downgrade reflects weaker expected growth in petrol and diesel demand due to elevated fuel costs, softer mobility trends and official efforts to conserve fuel amid the ongoing West Asia crisis.Petrol and diesel prices have been increased by around Rs 5 per litre in three instalments since May 15, after oil marketing companies passed on part of the burden of soaring global crude oil prices to consumers.

Petrol demand faces steepest downside risk

The report said petrol demand is likely to see the sharpest slowdown, with projected growth revised down by 25 kbd, from 63 kbd to 38 kbd.Petrol consumption is now estimated at 1,010 kbd, compared to the earlier estimate of 1,035 kbd.According to the report, weaker commuting activity, slower discretionary travel and government fuel-saving campaigns are expected to curb fuel consumption.Annual diesel demand growth was also cut by around 20 kbd, while jet fuel demand growth was nearly halved to about 6 kbd from 11 kbd earlier due to expectations of reduced air travel and tighter spending patterns.“The revisions primarily reflect weaker expected growth in gasoline and diesel demand as higher costs, weaker mobility trends, and recent government-led fuel conservation efforts increasingly feed into domestic transportation activity,” the report said, as quoted by PTI.

Rupee weakness, crude surge add pressure

The report noted that India’s macroeconomic environment has deteriorated since the escalation of the US-Iran conflict, with rising crude import costs, refinery expenses and rupee depreciation increasing inflationary pressure.The rupee has weakened by around 6 per cent since the conflict began and nearly 10 per cent over the past year. Foreign exchange reserves have also reportedly declined by about 4.3 per cent since late February as authorities attempted to stabilise the currency and contain imported inflation.The report said the current average petrol price of around Rs 103 per litre remains well below the estimated breakeven level of nearly Rs 125 per litre.Diesel prices near Rs 94 per litre are also below the estimated breakeven range of Rs 115-120 per litre.Before the recent price revisions, state-run fuel retailers were reportedly losing nearly Rs 1,000 crore daily because rising crude procurement costs and currency weakness outpaced retail fuel prices.“The key issue is the inability of state-run retailers to pass through rising import costs quickly enough to restore profitability,” the report said.

Russian crude continues to support supply security

The report added that India’s dependence on discounted Russian crude imports, estimated at around 1.9-2 million barrels per day, continues to provide stability to the domestic fuel market amid geopolitical uncertainty in West Asia.Policymakers now appear to be prioritising macroeconomic stability, inflation management, foreign exchange preservation and fuel supply security over near-term fuel demand growth.The report warned that unless crude prices ease significantly, the rupee stabilises or additional fiscal support measures are introduced, further fuel price hikes and stricter fuel-conservation measures may become difficult to avoid.



Source link

Continue Reading

Business

Scottish Government will be ‘bold, innovative and ambitious’ on industry – Flynn

Published

on

Scottish Government will be ‘bold, innovative and ambitious’ on industry – Flynn


The Scottish Government will be “bold, innovative and ambitious” in shaping Scotland’s industrial future, new Economy Secretary Stephen Flynn has said.

In his first official engagement in the role, Mr Flynn met former workers of the Grangemouth refinery and ExxonMobil Mossmorran ethylene plant, alongside Unite the union.

Last year, Grangemouth – Scotland’s only oil refinery – stopped processing crude oil after a century of operations.

Its closure meant the the loss of 430 of the 2,000 jobs based at the industrial complex.

In February, oil giant ExxonMobil closed its Mossmorran plastics plant in Fife with the loss of 400 jobs.

ExxonMobil’s ethylene plant at Mossmorran in Fife has been closed (Jane Barlow/PA) (PA Wire)

Mr Flynn said: “It has been heartening to hear more about the work that has been undertaken by a wide range of partners to support affected workers at Grangemouth and Mossmorran and drive positive outcomes for them and their families.”

He also visited the Grangemouth Industrial Complex to tour the facilities of Celtic Renewables, a biorefinery which has secured £11 million of Scottish Government and Scottish Enterprise funding.

The company is projected to create nearly 150 jobs by 2030.

He continued: “I was also pleased to visit Celtic Renewables, a growing success story which illustrates that there can – and must – be an incredibly bright and positive future for our industrial heartlands and the communities they support.

“It is imperative that we are bold, innovative and ambitious in collectively shaping Scotland’s industrial future. I will work to ensure strong, vibrant and indispensable industries – which have been let down by successive UK governments – are at the heart of Scotland’s economy.”

Scottish Enterprise chief executive Adrian Gillespie said: “It was great to join the Cabinet Secretary at Celtic Renewables and show first hand Scottish Enterprise’s continuing commitment to Grangemouth.

“Celtic Renewables is a strong example of an innovative, scaling company that has benefitted from Grangemouth’s excellent connectivity and skills, enabled by funding and support from Scottish Enterprise and our partners.

“We’ve worked with the company since its start-up in 2011 and continue to do so as it accelerates plans for a full-scale biorefinery creating more high-quality jobs.”



Source link

Continue Reading

Trending